285 related articles for article (PubMed ID: 29752743)
21. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
[TBL] [Abstract][Full Text] [Related]
23. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours.
Pedersen-Bjergaard J; Daugaard G; Hansen SW; Philip P; Larsen SO; Rørth M
Lancet; 1991 Aug; 338(8763):359-63. PubMed ID: 1713639
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy of refractory germ cell cancer with Etoposide.
Lederman GS; Garnick MB; Canellos GP; Richie JP
J Clin Oncol; 1983 Nov; 1(11):706-9. PubMed ID: 6321675
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors.
Nonomura N; Oka D; Nishimura K; Nakayama M; Inoue H; Mizutani Y; Miki T; Okuyama A
Int J Urol; 2007 Jun; 14(6):527-31. PubMed ID: 17593098
[TBL] [Abstract][Full Text] [Related]
26. Feasibility and usefulness of high-dose chemotherapy (high-dose ifosfamide, carboplatin and etoposide) combined with peripheral blood stem cell transplantation for male germ cell tumor: a single-institute experience.
Hara I; Miyake H; Yamada Y; Yamanaka K; Furukawa J; Kumano M; Takenaka A; Fujisawa M
Anticancer Drugs; 2006 Oct; 17(9):1057-66. PubMed ID: 17001179
[TBL] [Abstract][Full Text] [Related]
27. Therapy-related myeloid neoplasms following treatment with radioiodine.
Schroeder T; Kuendgen A; Kayser S; Kröger N; Braulke F; Platzbecker U; Klärner V; Zohren F; Haase D; Stadler M; Schlenk R; Czibere AG; Bruns I; Fenk R; Gattermann N; Haas R; Kobbe G; Germing U
Haematologica; 2012 Feb; 97(2):206-12. PubMed ID: 21993688
[TBL] [Abstract][Full Text] [Related]
28. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
Pedersen-Bjergaard J; Philip P; Larsen SO; Andersson M; Daugaard G; Ersbøll J; Hansen SW; Hou-Jensen K; Nielsen D; Sigsgaard TC
Leukemia; 1993 Dec; 7(12):1975-86. PubMed ID: 8255096
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial with etoposide (VP16) plus ifosfamide plus high-dose cisplatin (VIhP regimen) in refractory germ cell tumors.
Droz JP; Ribrag V; Ghosn M; Guimares J; Theodore C; Azab M; Ostronoff M; Mahjoubi M; Moran A; Pico J
Prog Clin Biol Res; 1989; 303():739-47. PubMed ID: 2550949
[No Abstract] [Full Text] [Related]
30. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report.
Heyn R; Khan F; Ensign LG; Donaldson SS; Ruymann F; Smith MA; Vietti T; Maurer HM
Med Pediatr Oncol; 1994; 23(2):99-106. PubMed ID: 8202048
[TBL] [Abstract][Full Text] [Related]
31. [Secondary leukemia following ultra high-dose chemotherapy with peripheral blood stem cell autotransplantation for refractory testicular cancer].
Matsumoto S; Matsuda H; Uejima S; Kurita T
Nihon Hinyokika Gakkai Zasshi; 2000; 91(10-11):687-91. PubMed ID: 11109821
[TBL] [Abstract][Full Text] [Related]
32. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial.
Lotz JP; Bui B; Gomez F; Théodore C; Caty A; Fizazi K; Gravis G; Delva R; Peny J; Viens P; Duclos B; De Revel T; Curé H; Gligorov J; Guillemaut S; Ségura C; Provent S; Droz JP; Culine S; Biron P;
Ann Oncol; 2005 Mar; 16(3):411-8. PubMed ID: 15659420
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue.
Broun ER; Nichols CR; Kneebone P; Williams SD; Loehrer PJ; Einhorn LH; Tricot GJ
Ann Intern Med; 1992 Jul; 117(2):124-8. PubMed ID: 1318648
[TBL] [Abstract][Full Text] [Related]
34. Lowered Cisplatin Dose and No Bleomycin in the Treatment of Pediatric Germ Cell Tumors: Results of the GCT-99 Protocol From the Brazilian Germ Cell Pediatric Oncology Cooperative Group.
Lopes LF; Macedo CR; Aguiar Sdos S; Barreto JH; Martins GE; Sonaglio V; Milone M; Lima ER; Almeida MT; Lopes PM; Watanabe FM; D'Andrea ML; Pianovski MA; Melaragno R; Vianna SM; Moreira ME; Bruniera P; de Oliveira CZ
J Clin Oncol; 2016 Feb; 34(6):603-10. PubMed ID: 26729441
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma.
Harstrick A; Schmoll HJ; Wilke H; Köhne-Wömpner CH; Stahl M; Schöber C; Casper J; Bruderek L; Schmoll E; Bokemeyer C
J Clin Oncol; 1991 Sep; 9(9):1549-55. PubMed ID: 1651992
[TBL] [Abstract][Full Text] [Related]
36. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.
Loehrer PJ; Lauer R; Roth BJ; Williams SD; Kalasinski LA; Einhorn LH
Ann Intern Med; 1988 Oct; 109(7):540-6. PubMed ID: 2844110
[TBL] [Abstract][Full Text] [Related]
37. Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes.
Necchi A; Nicolai N; Mariani L; Raggi D; Farè E; Giannatempo P; Catanzaro M; Biasoni D; Torelli T; Stagni S; Milani A; Piva L; Pizzocaro G; Gianni AM; Salvioni R
Ann Oncol; 2013 Nov; 24(11):2887-92. PubMed ID: 23860612
[TBL] [Abstract][Full Text] [Related]
38. Sequential intermediate high-dose therapy with etoposide, ifosfamide and cisplatin for patients with germ cell tumors.
Mardiak J; Fuchsberger P; Lakota J; Sálek T; Sycová-Milá Z; Drahokoupilová M; Baláz M; Koza I
Neoplasma; 2000; 47(4):239-43. PubMed ID: 11043829
[TBL] [Abstract][Full Text] [Related]
39. Oncological outcomes of metastatic testicular cancers under centralized management through regional medical network.
Inai H; Kawai K; Kojima T; Joraku A; Shimazui T; Yamauchi A; Miyagawa T; Endo T; Fukuhara Y; Miyazaki J; Uchida K; Nishiyama H
Jpn J Clin Oncol; 2013 Dec; 43(12):1249-54. PubMed ID: 24101656
[TBL] [Abstract][Full Text] [Related]
40. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
